| 摘要 |
The present invention relates to drug combinations and pharmaceutical com positions for treating cancer such as non-small cell lung carcinoma, said co mbination comprising (1) at least one substituted-diaryl urea such as BAY 43 -9006, (2) at least one taxane such as Paclitaxel (Taxol®), Docetaxel (Taxot ere®) and AbraxaneTM and (3) at least one platinum complex antineoplastic nu cleic acid binding agent such as carboplatin (Paraplatin®), oxaplatin (Eloxa tin®) and cisplatin (Platinol®), where any of these components can be presen t in the form of a pharmaceutically acceptable salt or other derivative ther eof.
|
